Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.

ABSTRACT:

Background

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (r/m HNSCC) are limited and prognosis is poor. The recent CheckMate 141 clinical trial demonstrated that nivolumab, an anti-programmed cell death protein 1 monoclonal antibody, was efficacious in extending the median overall survival (OS) in this patient population compared with standard therapies. We conducted a cost-effectiveness analysis to determine whether nivolumab is a cost-effective treatment in this patient population and examined various subgroups to determine for which, if any, the treatment is more cost-effective.

Materials and methods

We implemented a state transition model for HNSCC with a patient cohort who had tumor progression 6 mon

SUBMITTER: Zargar M 

PROVIDER: S-EPMC5813741 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature